生长抑素类似物在晚期胃肠胰神经内分泌肿瘤中的抗增殖作用：一项系统评价和荟萃分析。
Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
作者信息
Merola Elettra, Panzuto Francesco, Delle Fave Gianfranco
机构信息
Department of Digestive and Liver Diseases, Sapienza University, Sant'Andrea Hospital, Rome, Italy.
出版信息
Oncotarget. 2017 Jul 11;8(28):46624-46634. doi: 10.18632/oncotarget.16686.
A meta-analysis has systematically investigated the antineoplastic efficacy and safety of somatostatin analogs (SSAs) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). Randomized controlled trials (RCTs) reporting the hazard ratio (HR) for disease progression (DP) were evaluated. Response rate and risk ratio (RR) for adverse events were also analyzed. A total of 289 patients (143 receiving SSAs vs. 146 placebo) were evaluated from two RCTs. A significant benefit from SSAs in terms of disease control was observed (HR 0.41, 95% CI: 0.29 to 0.58, P < 0.01; I20%), response rate being 58.0% vs. 32.2%, respectively.The occurrence of adverse events significantly differed from the placebo arm only in terms of biliary stones (RR 3.79, 95% CI: 1.28 to 11.17, P = 0.02; I20%). In conclusion, SSAs showed an antiproliferative effect in advanced GEP-NETs, with a good safety profile.
一项荟萃分析系统地研究了生长抑素类似物（SSAs）在晚期胃肠胰神经内分泌肿瘤（GEP-NETs）中的抗肿瘤疗效和安全性。对报告疾病进展（DP）风险比（HR）的随机对照试验（RCT）进行了评估。还分析了不良事件的缓解率和风险比（RR）。两项RCT共评估了289例患者（143例接受SSAs治疗，146例接受安慰剂治疗）。观察到SSAs在疾病控制方面有显著益处（HR 0.41，95%CI：0.29至0.58，P<0.01；I²0%），缓解率分别为58.0%和32.2%。不良事件的发生仅在胆结石方面与安慰剂组有显著差异（RR 3.79，95%CI：1.28至11.17，P = 0.02；I²0%）。总之，SSAs在晚期GEP-NETs中显示出抗增殖作用，且安全性良好。
Zotero 插件